Expansion Therapeutics
PrivateLast Round
Series B
Sep 29, 2021
Total Funding Raised
$135.3M
Company Overview
Expansion Therapeutics is a biotechnology company that develops small molecule binders as transformative oral medicines aimed at treating severe RNA-mediated diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Expansion Therapeutics Comparables
Compare Expansion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ribometrix | 94% | |
| Arrakis Therapeutics | 94% | |
| Skyhawk Therapeutics | 89% |
Expansion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 29, 2021 | ||||
| Series A | Jan 3, 2018 | ||||
| Seed | May 31, 2017 |
Expansion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series B |
| RA Capital Management | Series A, Series B |
| Westlake Village BioPartners | Series B |
| Acks | Series A |
| Cormorant Asset Management | Series B |
| 5AM Ventures | Series B, Seed, Series A |
| Logos Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 29, 2021
$80M round led by Kleiner Perkins and Cormorant Asset Management.
- Jan 3, 2018
$55.3M round led by Kleiner Perkins and Novartis.
Expansion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Expansion Therapeutics's valuation, stock price, and market status.
Is Expansion Therapeutics a public or private company?
Expansion Therapeutics is a private company.
What is the current stock price of Expansion Therapeutics?
Expansion Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Expansion Therapeutics worth (valuation)?
Valuation information for Expansion Therapeutics is not publicly available.
Can I buy Expansion Therapeutics stock?
Expansion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Expansion Therapeutics's last funding round?
Expansion Therapeutics's most recent funding round was Series B on September 29, 2021.
Who are the main investors in Expansion Therapeutics?
Key investors in Expansion Therapeutics include RA Capital Management, 5AM Ventures, Sanofi Ventures, Kleiner Perkins, Cormorant Asset Management.
Will Expansion Therapeutics IPO soon?
No public IPO plans have been announced for Expansion Therapeutics.
How can I track Expansion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Expansion Therapeutics's secondary market activity and sign up for updates.